About Dendreon
Dendreon is a Healthcare company based in Seal Beach (United States) founded in 1992, and was acquired by Nanjing Xinbai in May 2018. Autologous dendritic cell immunotherapies are developed for cancer treatment. It operates on a HealthTech and Professional Services model. Dendreon has raised $21.7 million across 3 funding rounds from investors including New York Life Insurance, Nanjing Xinbai and Healthcare Ventures. Its website dendreon.com draws about 18 thousand monthly visits. Dendreon offers products and services including Provenge and Cellular Therapy Manufacturing. Its focus areas include Biotechnology and Cellular Therapy. Its legal entity is Dendreon Pharmaceuticals LLC. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Dendreon is engaged in the development and delivery of cellular therapies and immunotherapies aimed at improving patient outcomes. The company operates within the healthcare sector, specializing in biotechnology with a focus on innovative treatments like Provenge, an FDA-approved immunotherapy for prostate cancer. Strategic partnerships and research are leveraged to advance complex cell therapies. Manufacturing services are also provided to support other companies in bringing life-saving innovations to market.
- Headquarters Seal Beach, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website dendreon.com
- Social LinkedIn X Facebook YouTube
- Acquired by Nanjing Xinbai (May 2018)
- Legal Name Dendreon Pharmaceuticals Llc
- Total Equity Funding$21.7M (USD)
in 3 rounds
- Latest Funding Round$10M (USD), Series C
Oct 1999
- InvestorsNew York Life Insurance
& 6 more
- Acquired by
Products & Services of Dendreon
Dendreon offers a comprehensive portfolio of products and services, including Provenge and Cellular Therapy Manufacturing.
Provenge is used for advanced prostate cancer treatment.
Manufacturing support is provided for cellular therapy development.
Apps and channels of Dendreon
its YouTube channel Dendreon Pharmaceuticals has 39 subscribers and 14 videos.
Videos from Dendreon
The most watched videos on Dendreon's YouTube channel, Dendreon Pharmaceuticals (39 subscribers). Click a video to play it here.
More on Dendreon Pharmaceuticals.
Funding Insights of Dendreon
Dendreon has successfully raised a total of $21.7M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $10 million completed in October 1999. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.7M
- Total Rounds 3
- Last Round Series C — $10M
- Investors Count 5
All 3 funding rounds of Dendreon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 1999 | $10M | Series C | – | – | |
| Sep 1997 | $11.7M | Series B | – | – | |
| Jun 1996 | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Dendreon
Dendreon has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include New York Life Insurance, Nanjing Xinbai and Healthcare Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| hcven.com | ||||
Biomedical investment financing and active management services. | sanderling.com | |||
Private equity investments are backed by a single-family office firm. | capital.vulcan.com | Seattle, United States | ||
Early-stage tech startups are invested in by Rho Capital Partners. | rho.com | New York, United States | ||
Mutual life insurance and asset management services are provided. | 1845 | newyorklife.com | New York, United States | |
| sanpowergroup.com | ||||
AI-powered translation and localization services are provided globally. | 1952 | njxb.com | Nanjing, China |
Investor details for Dendreon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dendreon
106 people are tracked at Dendreon (18 in leadership, 88 in team).
| Name | Role | Group |
|---|---|---|
Patrick Stinson | Corporate Account Director-southeast | Leadership |
Drew Saelens | Director, Government Affairs And Advocacy | Leadership |
Bruce Johnson | Vice President, IMF Operations | Leadership |
Michelle Kelch | Director, Apheresis Operations | Leadership |
Amy Coachman | Head Of Marketing | Leadership |
Serena Stewart | Vice President, Patient Operations | Leadership |
Sherry Saurini | Head of Quality @Dendreon Pharmaceuticals | Leadership |
Ciriaco Mojica Jr. | Associate Director, Manufacturing Engineering | Leadership |
Bob Melkerson | Director of IT, Business Applications | Leadership |
Bev Eckert | Sr. Assistant to the VP& CIO | Leadership |
Kyle Jackson | Senior Director, Site Operations | Leadership |
Michael Allen | Vice president, Information Technology | Leadership |
Troy Hardwick, MBA | Director, Patient Operations | Leadership |
Matt Hammer | Sr Director Finance | Leadership |
Fang Wang | Deputy Chief Financial Officer | Leadership |
Khalid Mamlouk | Senior Director, Scientific Relations | Leadership |
Nadeem Sheikh | VP Research & Manufacturing Sciences | Leadership |
John Matthews | Director, Human Resources / HR Department Head | Leadership |
Jason Lunetta | Manager, Corporate Accounts At Dendreon | Team |
Eric Smith | Immunotherapy Sales Specialist | Team |
86 more people are available in the full profile.
Complete people profiles for Dendreon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Dendreon
6 dated milestones of Dendreon across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Dendreon is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $10.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Sanpower Group.
- Exit Acquired by Nanjing Xinbai.
Competitors of Dendreon
Dendreon has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Dendreon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dendreon
The website of Dendreon (dendreon.com) receives about 17.6K visits a month and ranks #885,568 among all websites worldwide, #1,067 in Biotechnology and Pharmaceuticals.
- Monthly visits17.6K
▲ 10.8% vs previous month
- Unique visitors6.5K
per month
- Global rank#885,568
among all websites
- Category rank#1,067
Health · Biotechnology and Pharmaceuticals
- Bounce rate71%
- Pages per visit8.5
- Average visit11 min 45 sec
- DevicesDesktop 19% · Mobile 81%
Websites whose visitors overlap most with Dendreon. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| exelixis.com | 100% | 39.1K | #1,001,350 | View details | |
| omeros.com | 99% | 15.6K | #1,695,799 | View details | |
| ariad.com | 98% | View details | |||
| rarecyte.com | 91% | 3.2K | #5,681,690 | View details | |
| shapetx.com | 83% | 2K | #11,569,347 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 34 similar websites and full traffic analytics for Dendreon
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 34 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as Dendreon (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dendreon
Complete news archive for Dendreon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dendreon
Dendreon was founded in 1992 and raised its 1st funding round 4 years after it was founded.
Dendreon is headquartered in Seal Beach, United States. It is registered at Seal Beach, California, United States.
Dendreon is a funded company, having raised a total of $21.7M across 3 funding rounds to date.
Dendreon is engaged in the development and delivery of cellular therapies and immunotherapies aimed at improving patient outcomes. The company operates within the healthcare sector, specializing in biotechnology with a focus on innovative treatments like Provenge, an FDA-approved immunotherapy for prostate cancer. Strategic partnerships and research are leveraged to advance complex cell therapies. Manufacturing services are also provided to support other companies in bringing life-saving innovations to market.
Dendreon offers Provenge and Cellular Therapy Manufacturing.
Dendreon has 7 investors. Key investors include New York Life Insurance, Nanjing Xinbai, Healthcare Ventures, Sanderling Ventures, and Vulcan Capital.
Dendreon operates through Dendreon Pharmaceuticals Llc.
Yes. Dendreon was acquired by Nanjing Xinbai in May 2018.